{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:16:14Z","timestamp":1789049774778,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40263-026-01325-5","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:05:59Z","timestamp":1786601159000},"page":"1369-1393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-1785","authenticated-orcid":false,"given":"Shakila","family":"Meshkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Meshkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1884-4973","authenticated-orcid":false,"given":"Qiaowei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillani","family":"Wijendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-0411","authenticated-orcid":false,"given":"Amy C.","family":"Reichelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2421-157X","authenticated-orcid":false,"given":"Yanbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9591-4355","authenticated-orcid":false,"given":"Lisa","family":"Burback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7297-1250","authenticated-orcid":false,"given":"Olga","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9097-900X","authenticated-orcid":false,"given":"Andrew","family":"Greenshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-0788","authenticated-orcid":false,"given":"Candice M.","family":"Monson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3040-7162","authenticated-orcid":false,"given":"Eric","family":"Vermetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6610-9365","authenticated-orcid":false,"given":"Rakesh","family":"Jetly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5590-8719","authenticated-orcid":false,"given":"Wendy","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-4483","authenticated-orcid":false,"given":"Richard J.","family":"Zeifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-1173","authenticated-orcid":false,"given":"Venkat","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1325_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacol Rev"},{"key":"1325_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83\u2013102. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.010.","journal-title":"Pharmacol Ther"},{"key":"1325_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R de la Torre","year":"2004","unstructured":"de la Torre R, Farr\u00e9 M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137\u201344. https:\/\/doi.org\/10.1097\/00007691-200404000-00009.","journal-title":"Ther Drug Monit"},{"key":"1325_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1017\/S109285291300045X","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013;18:171\u20134. https:\/\/doi.org\/10.1017\/S109285291300045X.","journal-title":"CNS Spectr"},{"key":"1325_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/psymed.2024.0039","volume":"4","author":"S Meshkat","year":"2026","unstructured":"Meshkat S, Fang H, Sousa-Ho R, et al. Therapeutic effects of low-dose psilocybin in depression and other mental disorders: a systematic review. Psychedel Med. 2026;4:54\u201367. https:\/\/doi.org\/10.1089\/psymed.2024.0039.","journal-title":"Psychedel Med"},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"e245960","DOI":"10.1001\/jamanetworkopen.2024.5960","volume":"7","author":"A Yerubandi","year":"2024","unstructured":"Yerubandi A, Thomas JE, Bhuiya N, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:e245960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5960.","journal-title":"JAMA Netw Open"},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","volume":"296","author":"NX Li","year":"2022","unstructured":"Li NX, Hu YR, Chen WN, Zhang B. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord. 2022;296:26\u201334. https:\/\/doi.org\/10.1016\/j.jad.2021.09.041.","journal-title":"J Affect Disord"},{"key":"1325_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/02791072.2020.1761573","volume":"52","author":"J Bornemann","year":"2020","unstructured":"Bornemann J. The viability of microdosing psychedelics as a strategy to enhance cognition and well-being: an early review. J Psychoact Drugs. 2020;52:300\u20138. https:\/\/doi.org\/10.1080\/02791072.2020.1761573.","journal-title":"J Psychoact Drugs"},{"key":"1325_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115531","volume":"329","author":"S Haikazian","year":"2023","unstructured":"Haikazian S, Chen-Li DCJ, Johnson DE, et al. Psilocybin-assisted therapy for depression: a systematic review and meta-analysis. Psychiatry Res. 2023;329:115531. https:\/\/doi.org\/10.1016\/j.psychres.2023.115531.","journal-title":"Psychiatry Res"},{"key":"1325_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.11.008","volume":"75","author":"T Lea","year":"2020","unstructured":"Lea T, Amada N, Jungaberle H, Schecke H, Klein M. Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy. 2020;75:102600. https:\/\/doi.org\/10.1016\/j.drugpo.2019.11.008.","journal-title":"Int J Drug Policy"},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/02791072.2024.2424284","volume":"58","author":"OA Syed","year":"2026","unstructured":"Syed OA, Petranker R, Fewster EC, et al. Global trends in psychedelic microdosing: demographics, substance testing behavior, and patterns of use. J Psychoact Drugs. 2026;58:18\u201328. https:\/\/doi.org\/10.1080\/02791072.2024.2424284.","journal-title":"J Psychoact Drugs"},{"key":"1325_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1455072517753339","volume":"35","author":"PG Johnstad","year":"2018","unstructured":"Johnstad PG. Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nord Stud Alcohol Drugs. 2018;35:39\u201351. https:\/\/doi.org\/10.1177\/1455072517753339.","journal-title":"Nord Stud Alcohol Drugs"},{"key":"1325_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","volume":"236","author":"T Anderson","year":"2019","unstructured":"Anderson T, Petranker R, Rosenbaum D, et al. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology. 2019;236:731\u201340. https:\/\/doi.org\/10.1007\/s00213-018-5106-2.","journal-title":"Psychopharmacology"},{"key":"1325_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.bpsc.2024.01.002","volume":"9","author":"RJ Murphy","year":"2024","unstructured":"Murphy RJ, Muthukumaraswamy S, de Wit H. Microdosing psychedelics: current evidence from controlled studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:500\u201311. https:\/\/doi.org\/10.1016\/j.bpsc.2024.01.002.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1325_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","volume":"22","author":"NRPW Hutten","year":"2019","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol. 2019;22:426\u201334. https:\/\/doi.org\/10.1093\/ijnp\/pyz029.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1325_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03013-8","volume":"14","author":"NRPW Hutten","year":"2024","unstructured":"Hutten NRPW, Quaedflieg CWEM, Mason NL, et al. Inter-individual variability in neural response to low doses of LSD. Transl Psychiatry. 2024;14:288. https:\/\/doi.org\/10.1038\/s41398-024-03013-8.","journal-title":"Transl Psychiatry"},{"key":"1325_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","volume":"41","author":"NRPW Hutten","year":"2020","unstructured":"Hutten NRPW, Mason NL, Dolder PC, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo-controlled dose-effect finding study. Eur Neuropsychopharmacol. 2020;41:81\u201391. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.10.002.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1325_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02900-4","volume":"14","author":"N Allen","year":"2024","unstructured":"Allen N, Jeremiah A, Murphy R, et al. LSD increases sleep duration the night after microdosing. Transl Psychiatry. 2024;14:191. https:\/\/doi.org\/10.1038\/s41398-024-02900-4.","journal-title":"Transl Psychiatry"},{"key":"1325_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bpsc.2019.12.007","volume":"5","author":"AK Bershad","year":"2020","unstructured":"Bershad AK, Preller KH, Lee R, et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:461\u20137. https:\/\/doi.org\/10.1016\/j.bpsc.2019.12.007.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1325_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41386-022-01479-y","volume":"48","author":"J Glazer","year":"2023","unstructured":"Glazer J, Murray CH, Nusslock R, Lee R, de Wit H. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology. 2023;48:418\u201326. https:\/\/doi.org\/10.1038\/s41386-022-01479-y.","journal-title":"Neuropsychopharmacology"},{"key":"1325_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-024-00844-5","volume":"25","author":"RJ Murphy","year":"2024","unstructured":"Murphy RJ, Godfrey K, Shaw AD, Muthukumaraswamy S, Sumner RL. Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial. BMC Neurosci. 2024;25:7. https:\/\/doi.org\/10.1186\/s12868-024-00844-5.","journal-title":"BMC Neurosci"},{"key":"1325_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","volume":"94","author":"RJ Murphy","year":"2023","unstructured":"Murphy RJ, Sumner R, Evans W, et al. Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial. Biol Psychiatry. 2023;94:511\u201321. https:\/\/doi.org\/10.1016\/j.biopsych.2023.03.013.","journal-title":"Biol Psychiatry"},{"key":"1325_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/02698811211050556","volume":"36","author":"J Marschall","year":"2022","unstructured":"Marschall J, Fejer G, Lempe P, et al. Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study. J Psychopharmacol. 2022;36:97\u2013113. https:\/\/doi.org\/10.1177\/02698811211050556.","journal-title":"J Psychopharmacol"},{"key":"1325_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13143","volume":"27","author":"H de Wit","year":"2022","unstructured":"de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: a placebo-controlled, dose\u2013response study. Addict Biol. 2022;27:e13143. https:\/\/doi.org\/10.1111\/adb.13143.","journal-title":"Addict Biol"},{"key":"1325_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02039-0","volume":"12","author":"F Cavanna","year":"2022","unstructured":"Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12:307. https:\/\/doi.org\/10.1038\/s41398-022-02039-0.","journal-title":"Transl Psychiatry"},{"key":"1325_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106493","volume":"180","author":"N Pinhas","year":"2026","unstructured":"Pinhas N, Eidlman N, Barnea A, Peled-Avron L. Effects of psychedelic microdosing on cognitive functions: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2026;180:106493. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106493.","journal-title":"Neurosci Biobehav Rev"},{"key":"1325_CR27","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.23r03581","volume":"26","author":"DF Lo","year":"2024","unstructured":"Lo DF, Zia H, Rajkumar P, Thakur A, O\u2019Donnell H. Modern psychedelic microdosing research on mental health: a systematic review. Prim Care Companion CNS Disord. 2024;26:23r03581. https:\/\/doi.org\/10.4088\/PCC.23r03581.","journal-title":"Prim Care Companion CNS Disord"},{"key":"1325_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110402","volume":"271","author":"S Modzelewski","year":"2025","unstructured":"Modzelewski S, Stankiewicz A, Waszkiewicz N, \u0141ukasiewicz K. Side effects of microdosing lysergic acid diethylamide and psilocybin: a systematic review of potential physiological and psychiatric outcomes. Neuropharmacology. 2025;271:110402. https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110402.","journal-title":"Neuropharmacology"},{"key":"1325_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0269881120953994","volume":"36","author":"R Petranker","year":"2022","unstructured":"Petranker R, Anderson T, Maier LJ, Barratt MJ, Ferris JA, Winstock AR. Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention. J Psychopharmacol. 2022;36:85\u201396. https:\/\/doi.org\/10.1177\/0269881120953994.","journal-title":"J Psychopharmacol"},{"key":"1325_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Br Med J. 2020;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"Br Med J"},{"key":"1325_CR31","doi-asserted-by":"publisher","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI manual for evidence synthesis. JBI; 2024. https:\/\/doi.org\/10.46658\/JBIMES-24-01.","DOI":"10.46658\/JBIMES-24-01"},{"issue":"1","key":"1325_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-orgpsych-031921-021922","volume":"10","author":"SB Morris","year":"2023","unstructured":"Morris SB. Meta-analysis in organizational research: a guide to methodological options. Annu Rev Organ Psychol Organ Behav. 2023;10(1):225\u201359.","journal-title":"Annu Rev Organ Psychol Organ Behav"},{"key":"1325_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"1325_CR34","doi-asserted-by":"publisher","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","DOI":"10.18637\/jss.v036.i03"},{"key":"1325_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1037\/1082-989X.7.1.105","volume":"7","author":"SB Morris","year":"2002","unstructured":"Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7:105\u201325. https:\/\/doi.org\/10.1037\/1082-989X.7.1.105.","journal-title":"Psychol Methods"},{"key":"1325_CR36","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions. Version 6.5 (updated August 2024). Cochrane; 2024. https:\/\/www.cochrane.org\/handbook. Accessed 19 June 2026."},{"key":"1325_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","volume":"237","author":"N Family","year":"2020","unstructured":"Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low-dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology. 2020;237:841\u201353. https:\/\/doi.org\/10.1007\/s00213-019-05417-7.","journal-title":"Psychopharmacology"},{"key":"1325_CR38","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00213-021-06006-3","volume":"239","author":"I Wie\u00dfner","year":"2022","unstructured":"Wie\u00dfner I, Falchi M, Palhano-Fontes F, et al. Low-dose LSD and the stream of thought: increased discontinuity of mind, deep thoughts and abstract flow. Psychopharmacology. 2022;239:1721\u201333. https:\/\/doi.org\/10.1007\/s00213-021-06006-3.","journal-title":"Psychopharmacology"},{"key":"1325_CR39","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62878","volume":"10","author":"B Szigeti","year":"2021","unstructured":"Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878. https:\/\/doi.org\/10.7554\/eLife.62878.","journal-title":"eLife"},{"key":"1325_CR40","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","volume":"236","author":"S Yanakieva","year":"2019","unstructured":"Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology. 2019;236:1159\u201370. https:\/\/doi.org\/10.1007\/s00213-018-5119-x.","journal-title":"Psychopharmacology"},{"key":"1325_CR41","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00213-021-05991-9","volume":"239","author":"CH Murray","year":"2022","unstructured":"Murray CH, Tare I, Perry CM, Malina M, Lee R, de Wit H. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology. 2022;239:1735\u201347. https:\/\/doi.org\/10.1007\/s00213-021-05991-9.","journal-title":"Psychopharmacology"},{"key":"1325_CR42","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86:792\u2013800. https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.019.","journal-title":"Biol Psychiatry"},{"key":"1325_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00213-024-06680-z","volume":"242","author":"RJ Murphy","year":"2025","unstructured":"Murphy RJ, Sumner RL, Godfrey K, et al. Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide. Psychopharmacology. 2025;242:337\u201351. https:\/\/doi.org\/10.1007\/s00213-024-06680-z.","journal-title":"Psychopharmacology"},{"key":"1325_CR44","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0269881120940937","volume":"35","author":"JG Ramaekers","year":"2021","unstructured":"Ramaekers JG, Hutten NRPW, Mason NL, et al. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol. 2021;35:398\u2013405. https:\/\/doi.org\/10.1177\/0269881120940937.","journal-title":"J Psychopharmacol"},{"key":"1325_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/20494637251371626","volume":"19","author":"M Cavarra","year":"2025","unstructured":"Cavarra M, Hutten NRPW, Schepers J, et al. A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15\u00a0\u03bcg) on pain perception in healthy volunteers. Br J Pain. 2025;19:434\u201345. https:\/\/doi.org\/10.1177\/20494637251371626.","journal-title":"Br J Pain"},{"key":"1325_CR46","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00213-021-05857-0","volume":"239","author":"M van Elk","year":"2022","unstructured":"van Elk M, Fejer G, Lempe P, et al. Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study. Psychopharmacology. 2022;239:1705\u201320. https:\/\/doi.org\/10.1007\/s00213-021-05857-0.","journal-title":"Psychopharmacology"},{"key":"1325_CR47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/02791072.2022.2080616","volume":"55","author":"V Hartong","year":"2023","unstructured":"Hartong V, van Emmerik A. Psychedelic microdosing, mindfulness, and anxiety: a cross-sectional mediation study. J Psychoactive Drugs. 2023;55:310\u201320. https:\/\/doi.org\/10.1080\/02791072.2022.2080616.","journal-title":"J Psychoactive Drugs"},{"key":"1325_CR48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/00049530.2021.1882266","volume":"73","author":"S Bright","year":"2021","unstructured":"Bright S, Gringart E, Blatchford E, Bettinson S. A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, wellbeing and personality variables. Aust J Psychol. 2021;73:134\u201343. https:\/\/doi.org\/10.1080\/00049530.2021.1882266.","journal-title":"Aust J Psychol"},{"key":"1325_CR49","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1007\/s00213-018-5049-7","volume":"235","author":"L Prochazkova","year":"2018","unstructured":"Prochazkova L, Lippelt DP, Colzato LS, Kuchar M, Sjoerds Z, Hommel B. Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Psychopharmacology. 2018;235:3401\u201313. https:\/\/doi.org\/10.1007\/s00213-018-5049-7.","journal-title":"Psychopharmacology"},{"key":"1325_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1556\/2054.2021.00157","volume":"5","author":"HM Dressler","year":"2021","unstructured":"Dressler HM, Bright SJ, Polito V. Exploring the relationship between microdosing, personality and emotional insight: a prospective study. J Psychedel Stud. 2021;5:9\u201316. https:\/\/doi.org\/10.1556\/2054.2021.00157.","journal-title":"J Psychedel Stud"},{"key":"1325_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14512-3","volume":"12","author":"JM Rootman","year":"2022","unstructured":"Rootman JM, Kiraga M, Kryskow P, et al. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Sci Rep. 2022;12:11091. https:\/\/doi.org\/10.1038\/s41598-022-14512-3.","journal-title":"Sci Rep"},{"key":"1325_CR52","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/02698811241254831","volume":"38","author":"V Polito","year":"2024","unstructured":"Polito V, Liknaitzky P. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. J Psychopharmacol. 2024;38:701\u201311. https:\/\/doi.org\/10.1177\/02698811241254831.","journal-title":"J Psychopharmacol"},{"key":"1325_CR53","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2206443.","journal-title":"N Engl J Med"},{"key":"1325_CR54","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","volume":"322","author":"K Ko","year":"2023","unstructured":"Ko K, Kopra EI, Cleare AJ, Rucker JJ. Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis. J Affect Disord. 2023;322:194\u2013204. https:\/\/doi.org\/10.1016\/j.jad.2022.09.168.","journal-title":"J Affect Disord"},{"key":"1325_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","volume":"5","author":"JD Rosenblat","year":"2024","unstructured":"Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment-resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. Med (N Y). 2024;5:190\u2013200.e5. https:\/\/doi.org\/10.1016\/j.medj.2024.01.005.","journal-title":"Med (N Y)"},{"key":"1325_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/psymed.2024.0032","volume":"3","author":"S Meshkat","year":"2025","unstructured":"Meshkat S, Kaczmarek E, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment-resistant depression in bipolar II disorder. Psychedelic Med. 2025;3:53\u20138. https:\/\/doi.org\/10.1089\/psymed.2024.0032.","journal-title":"Psychedelic Med"},{"key":"1325_CR57","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1017\/S003329172000389X","volume":"50","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Shechet B, Nicholas CR, et al. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med. 2020;50:2655\u201366. https:\/\/doi.org\/10.1017\/S003329172000389X.","journal-title":"Psychol Med"},{"key":"1325_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1076459","volume":"13","author":"MI Husain","year":"2023","unstructured":"Husain MI, Ledwos N, Fellows E, et al. Serotonergic psychedelics for depression: what do we know about neurobiological mechanisms of action? Front Psychiatry. 2023;13:1076459. https:\/\/doi.org\/10.3389\/fpsyt.2022.1076459.","journal-title":"Front Psychiatry"},{"key":"1325_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5498\/wjp.v11.i6.201","volume":"11","author":"H Artin","year":"2021","unstructured":"Artin H, Zisook S, Ramanathan D. How do serotonergic psychedelics treat depression: the potential role of neuroplasticity. World J Psychiatry. 2021;11:201\u201314. https:\/\/doi.org\/10.5498\/wjp.v11.i6.201.","journal-title":"World J Psychiatry"},{"key":"1325_CR60","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","volume":"51","author":"J Fadiman","year":"2019","unstructured":"Fadiman J, Korb S. Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoact Drugs. 2019;51:118\u201322. https:\/\/doi.org\/10.1080\/02791072.2019.1593561.","journal-title":"J Psychoact Drugs"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01325-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:59:59Z","timestamp":1789048799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01325-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01325-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lisa Burback, Olga Winkler, and Yanbo Zhang are supported by the Academic Medicine and Health Services Program (AMHSP), a joint program funded by the University of Alberta and Alberta Health Services to ensure physicians affiliated with Alberta\u2019s faculties of medicine are compensated for providing patient care along with their work related to research, innovation, education, administration, and leadership. Rakesh Jetly is the CMO of Mydecine Innovation Group. Venkat Bhat is supported by an Academic Scholar Award from the University of Toronto Department of Psychiatry and has received research funding from the Canadian Institutes of Health Research, Brain & Behavior Foundation, Ontario Ministry of Health Innovation Funds, Royal College of Physicians and Surgeons of Canada, Department of National Defence (Government of Canada), New Frontiers in Research Fund, Associated Medical Services Inc. Healthcare, American Foundation for Suicide Prevention, Roche Canada, Novartis, and Eisai.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and analyzed during the current study are available upon request from the corresponding author.","order":2,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shakila Meshkat (Sh.M.) and Venkat Bhat (V.B.) contributed to the study conception, design, and methodology. Sh.M., Marco Leung (M.L.), Sarina Meshkat (Sa.M.), Dillani Wijendran (D.W.), Qiaowei Lin (Q.L.), and V.B. performed the investigation and contributed to data curation. Q.L. conducted the formal analysis and software-related work. Sh.M., M.L., Sa.M., D.W., Q.L., and V.B. drafted the initial manuscript. Amy C. Reichelt (A.C.R.), Yanbo Zhang (Y.Z.), Lisa Burback (L.B.), Olga Winkler (O.W.), Andrew Greenshaw (A.G.), Candice M. Monson (C.M.M.), Eric Vermetten (E.V.), Rakesh Jetly (R.J.), Wendy Lou (W.L.), Richard J. Zeifman (R.J.Z.), and all other authors critically reviewed and edited the manuscript for important intellectual content. V.B. provided supervision. All authors have read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","label":"Authors Contribution","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and\/or meta-analysis based on previously published data. As no new data were collected from human participants, ethics approval and informed consent were not required.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data and analytic code that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}